Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure

Circulation Research

Volumn 103, Issue 6, 2008, Pages 662-670

  Panchatcharam, Manikandan ^a   Miriyala, Sumitra ^a   Yang, Fanmuyi ^a   Rojas, Mauricio ^b   End, Christopher ^b   Vallant, Christopher ^b   Dong, Anping ^a   Lynch, Kevin ^c   Chun, Jerold ^d   Morris, Andrew J ^a   Smyth, Susan S ^a,b,e,f  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e LEXINGTON VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Arterial injury; Lipids; Lysophosphatidic acid; Vascular remodeling; Vascular smooth muscle cells

Indexed keywords

AUTOTAXIN; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 2; LYSOPHOSPHOLIPASE; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ISOPROTEIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CAROTID ARTERY LIGATION; CELL DIFFERENTIATION; CELL ISOLATION; CELL MIGRATION; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD PRESSURE; CELL MOTION; COMPARATIVE STUDY; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; THORACIC AORTA; TRANSGENIC MOUSE; VASCULAR DISEASE;

ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; CELL MOVEMENT; LYSOPHOSPHOLIPIDS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; PROTEIN ISOFORMS; RECEPTORS, LYSOPHOSPHATIDIC ACID; VASCULAR DISEASES;

EID: 53249144492     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.180778     Document Type: Article

References (33)

1. Kawai-Kowase K, Owens GK. Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Am J Physiol Cell Physiol. 2007;292:C59-C69.
2. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995;75:487-517.
3. Hayashi K, Takahashi M, Nishida W, Yoshida K, Ohkawa Y, Kitabatake A, Aoki J, Arai H, Sobue K. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ Res. 2001;89:251-258.
4. Xu YJ, Aziz OA, Bhugra P, Arneja AS, Mendis MR, Dhalla NS. Potential role of lysophosphatidic acid in hypertension and atherosclerosis. Can J Cardiol. 2003;19:1525-1536.
5. Siess W, Tigyi G. Thrombogenic and atherogenic activities of lysophos-phatidic acid. J Cell Biochem. 2004;92:1086-1094.
6. Tokumura A, Iimori M, Nishioka Y, Kitahara M, Sakashita M, Tanaka S. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am J Physiol. 1994;267: C204-C210.
7. Schmitz U, Thommes K, Beier I, Vetter H. Lysophosphatidic acid stimulates p21-activated kinase in vascular smooth muscle cells. Biochem Biophys Res Commun. 2002;291:687-691.
8. Gennero I, Xuereb JM, Simon MF, Girolami JP, Bascands JL, Chap H, Boneu B, Sie P. Effects of lysophosphatidic acid on proliferation and cytosolic Ca+ + of human adult vascular smooth muscle cells in culture. Thromb Res. 1999;94:317-326.
9. Damirin A, Tomura H, Komachi M, Liu JP, Mogi C, Tobo M, Wang JQ, Kimura T, Kuwabara A, Yamazaki Y, Ohta H, Im DS, Sato K, Okajima F. Role of lipoprotein-associated lysophospholipids in migratory activity of coronary artery smooth muscle cells. Am J Physiol Heart Circ Physiol. 2007;292:H2513-H2522.
10. Gardell SE, Dubin AE, Chun J. Emerging medicinal roles for lysophos-pholipid signaling. Trends Mol Med. 2006;12:65-75.
11. McIntyre TM, Pontsler AV, Silva AR, St HA, Xu Y, Hinshaw JC, Zimmerman GA, Hama K, Aoki J, Arai H, Prestwich GD. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci USA. 2003;100: 131-136. (Pubitemid 36078041)
12. Gaits F, Fourcade O, Le BF, Gueguen G, Gaige B, Gassama-Diagne A, Fauvel J, Salles JP, Mauco G, Simon MF, Chap H. Lysophosphatidic acid as a phospholipid mediator: pathways of synthesis. FEBS Lett. 1997;410: 54-58.
13. Gerrard JM, Robinson P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim Biophys Acta. 1989;1001:282-285.
14. Sano T, Baker D, Virag T, Wada A, Yatomi Y, Kobayashi T, Igarashi Y, Tigyi G. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem. 2002;277:21197-21206.
15. Tokumura A, Harada K, Fukuzawa K, Tsukatani H. Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma. Biochim Biophys Acta. 1986;875:31-38.
16. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, Clezardin P, Peyruchaud O. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 2004;114:1714-1725.
17. Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T, Mizuno K, Saku K, Taguchi R, Arai H. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem. 2002;277: 48737-48744.
18. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J. 1993;291:677-680.
19. Siess W, Zangl KJ, Essler M, Bauer M, Brandl R, Corrinth C, Bittman R, Tigyi G, Aepfelbacher M. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci USA. 1999;96:6931-6936.
20. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J, Arai H. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem. 2006;281:25822-25830.
21. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradere JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Moolenaar WH, Jonkers J. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol. 2006;26:5015-5022.
22. Federico L, Pamuklar Z, Liu S, Goto M, Dong A, Berdyshev E, Natarajan V, Fang F, Mills GB, Morris AJ, Smyth SS. Overexpression of autotoxin/ lysophospholipase D reveals a novel path for regulation of hemostasis in mice. Blood. 2007;110:3649.
23. Tokumura A, Fukuzawa K, Tsukatani H. Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species. Lipids. 1978;13:572-574.
24. Tigyi G, Hong L, Yakubu M, Parfenova H, Shibata M, Leffler CW. Lysophosphatidic acid alters cerebrovascular reactivity in piglets. Am J Physiol. 1995;268:H2048-H2055.
25. Yoshida K, Nishida W, Hayashi K, Ohkawa Y, Ogawa A, Aoki J, Arai H, Sobue K. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation. 2003;108: 1746-1752.
26. Zhang C, Baker DL, Yasuda S, Makarova N, Balazs L, Johnson LR, Marathe GK, McIntyre TM, Xu Y, Prestwich GD, Byun HS, Bittman R, Tigyi G. Lysophosphatidic acid induces neointima formation through PPARgamma activation. J Exp Med. 2004;199:763-774.
27. Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci U S A. 2000;97:13384-13389.
28. Contos JJ, Ishii I, Fukushima N, Kingsbury MA, Ye X, Kawamura S, Brown JH, Chun J. Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol Cell Biol. 2002;22:6921-6929.
29. Kumar PP, Good RR, Linder J. Complete response of granulosa cell tumor metastatic to liver after hepatic irradiation: a case report. Obstet Gynecol. 1986;67:95S-8S.
30. Myers DL, Liaw L. Improved analysis of the vascular response to arterial ligation using a multivariate approach. Am J Pathol. 2004; 164:43-48.
31. Liu P, Patil S, Rojas M, Fong AM, Smyth SS, Patel DD. CX3CR1 deficiency confers protection from intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol. 2006;26:2056-2062.
32. Smyth SS, Reis ED, Zhang W, Fallon JT, Gordon RE, Coller BS. Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation. 2001; 103:2501-2507.
33. Heasley BH, Jarosz R, Carter KM, Van SJ, Lynch KR, Macdonald TL. A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist. Bioorg Med Chem Lett. 2004;14: 4069-4074.